Journal Article

Central nervous system (CNS) tumors pose a major global health challenge, particularly in low- and middle-income countries (LMICs), where outcomes remain disproportionately poor. The global CONCORD-3 study (Lancet Oncology) highlighted stark disparities in five-year survival (2010-2014): from ∼15% in Thailand to 46% in Japan among adults, and from ∼ 80% in Denmark to < 40% in Brazil among children. [...]

EWSR1::FLI1 is an established oncogenic driver of Ewing sarcoma, a malignant round cell sarcoma, while EWSR1::PBX3 fusions have been associated with myoepithelioma, in particular the syncytial type, which is characterized by cutaneous predilection, syncytial growth and co-expression of S100 and EMA in the absence of cytokeratin expression. We recently reported two cases of basaloid neoplasms with adnexal differentiation harboring EWSR1::FLI1 and EWSR1::PBX3 fusions. [...]

Epithelial ovarian cancer (OC) is frequently diagnosed at an advanced stage, and despite surgery and chemotherapy, 70-80 % of patients relapse and die. Overcoming therapy resistance, e.g. [...]

Extrachromosomal DNA (ecDNA) contributes to cancer genome instability by enabling high-copy oncogene amplification and genetic intratumoral heterogeneity. Micronuclei (MNs) are common in chromosomally unstable cancers, yet their role in ecDNA-driven tumors remains unclear. [...]

Available epidemiological evidence shows that many cancers share familial risks, and this is increasingly confirmed by data on shared pathogenic germline gene variants between cancers. We decided to harness the world's largest resource on familial cancer to assess discordant familial risks for female breast (BC), prostate (PC), colorectal (CRC), and lung (LC) cancers with any of 22 different cancers in first-degree relatives (proband cancers). [...]

Currently, no immunotherapy is approved for T cell acute lymphoblastic leukemia (T‑ALL). High initial response rates to CD7‑directed chimeric antigen receptor (CAR) T cells are limited by profound T cell aplasia and CD7‑negative immune escape, underscoring the need for alternative targets. [...]